Diabetic Retinopathy: Battling the Global Epidemic

Das, Arup

doi:10.1167/iovs.16-21031

Cited by 50 publications

(26 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from a phase II clinical trial showed that, unexpectedly, not only did anti‐CCL2 therapy not improve the condition, but all treated patients had faster disease progression when compared to placebo control and over 50% of the patients treated with the highest dose of anti‐CCL2 suffered severe side effects (Raghu et al, ). These results caution against the use of anti‐CCL2 antibodies to treat ocular disease, which is now being considered (Das, ).…”

Section: Discussionmentioning

confidence: 99%

miR‐30a‐5p inhibition promotes interaction of Fas⁺endothelial cells and FasL⁺microglia to decrease pathological neovascularization and promote physiological angiogenesis

Murinello

Usui

Sakimoto

et al. 2018

Glia

View full text Add to dashboard Cite

Ischemia‐induced angiogenesis contributes to various neuronal and retinal diseases, and often results in neurodegeneration and visual impairment. Current treatments involve the use of anti‐VEGF agents but are not successful in all cases. In this study we determined that miR‐30a‐5p is another important mediator of retinal angiogenesis. Using a rodent model of ischemic retinopathy, we show that inhibiting miR‐30a‐5p reduces neovascularization and promotes tissue repair, through modulation of microglial and endothelial cell cross‐talk. miR‐30a‐5p inhibition results in increased expression of the death receptor Fas and CCL2, to decrease endothelial cell survival and promote microglial migration and phagocytic function in focal regions of ischemic injury. Our data suggest that miR‐30a‐5p inhibition accelerates tissue repair by enhancing FasL–Fas crosstalk between microglia and endothelial cells, to promote endothelial cell apoptosis and removal of dead endothelial cells. Finally, we found that miR‐30a levels were increased in the vitreous of patients with proliferative diabetic retinopathy. Our study identifies a role for miR‐30a in the pathogenesis of neovascular retinal disease by modulating microglial and endothelial cell function, and suggests it may be a therapeutic target to treat ischemia‐mediated conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

miR‐30a‐5p inhibition promotes interaction of Fas⁺endothelial cells and FasL⁺microglia to decrease pathological neovascularization and promote physiological angiogenesis

Murinello

Usui

Sakimoto

et al. 2018

Glia

View full text Add to dashboard Cite

show abstract

“…Approximately one-third of the 285 million people with Diabetes Mellitus (DM) worldwide suffer from DR, and the prevalence of Diabetes Mellitus (DM) is expected to increase to about 552 million in 2030 [3]. This makes DR a serious health problem in ophthalmology, which is only expected to increase in the oncoming years [4]. Early detection and frequent monitoring of the retina is necessary to ensure adequate and timely treatment [4].…”

Section: Introductionmentioning

confidence: 99%

“…This makes DR a serious health problem in ophthalmology, which is only expected to increase in the oncoming years [4]. Early detection and frequent monitoring of the retina is necessary to ensure adequate and timely treatment [4].…”

Section: Introductionmentioning

confidence: 99%

The spatial relation of diabetic retinal neurodegeneration with diabetic retinopathy

et al. 2020

View full text Add to dashboard Cite

Diabetic retinal neurodegeneration (DRN) has been demonstrated in eyes of patients with diabetes mellitus (DM), even in the absence of diabetic retinopathy (DR). However, no studies have looked at the rate of change in retinal layers and presence/development of DR over time per quadrant of the macula. In this longitudinal study, we aimed to clarify whether the rate of DRN is associated with the development/presence of DR within 4 different quadrants of the retina. Methods 80 eyes of 40 patients with type 1 DM and no/minimal DR were included. At 4 visits over 6 years, SD-OCT and fundus images were acquired. Thickness of the Retinal Nerve Fiber Layer (RNFL), Ganglion Cell Layer (GCL) and Inner Plexiform Layer (IPL) was measured in a 1-6mm circle around the fovea overall and for each quadrant (superior, nasal, inferior, temporal). Fundus images were scored for the presence/absence of DR in these areas. Multilevel analyses were performed to determine the rate of change for each layer overall and per quadrant for eyes/quadrants without and with DR during the follow-up period. Results RNFL and GCL showed significant thinning over time, IPL significant thickening. These changes were more pronounced for GCL and IPL in eyes/quadrants with DR during the follow-up period. Conclusions RNFL and GCL both showed thinning over time, which was more pronounced in eyes with DR for GCL. This holds true even in regional parts of the retina, as quadrant analyses

show abstract

“…Diabetic retinopathy (DR) is a serious complication of diabetes and is primarily caused by increased permeability of retinal vessels (diabetic macular edema) or the proliferation of new retina vessels following tissue hyperglycemia and hypoxemia [ 1 ]. As the disease progresses, the retinal neovasculature ruptures, resulting in blood accumulation in the vitreous with further visual impairment or even blindness, which seriously effects a patient's life and leads to a huge economic burden [ 2 , 3 ]. An estimated 93 million people worldwide are affected by DR [ 4 ], being the leading cause of blindness in adults in developed countries [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Network Pharmacology-based Investigation of the Underlying Mechanism of Panax notoginseng Treatment of Diabetic Retinopathy

Piao

Sun

Jin

et al. 2020

CCHTS

View full text Add to dashboard Cite

Background: Panax notoginseng, a Chinese herbal medicine, has been widely used to treat vascular diseases. Diabetic retinopathy (DR) is one of the complications of diabetic microangiopathy. According to recent studies, the application of Panax notoginseng extract and related Chinese patent medicine preparations can significantly improve DR. However, the pharmacological mechanisms remain unclear. Therefore, the purpose of this study was to decipher the potential mechanism of Panax notoginseng treatment of DR using network pharmacology. Methods: We evaluated and screened the active compounds of Panax notoginseng using the Traditional Chinese Medicine Systems Pharmacology database and collected potential targets of the compounds by target fishing. A multi-source database was also used to organize targets of DR. The potential targets as the treatment of DR with Panax notoginseng were then obtained by matching the compound targets with the DR targets. Using protein-protein interaction networks and topological analysis, interactions between potential targets were identified. In addition, we also performed gene ontology-biological process and pathway enrichment analysis for the potential targets by using the Biological Information Annotation Database. Results: Eight active ingredients of Panax notoginseng and 31 potential targets for the treatment of DR were identified. The screening and enrichment analysis revealed that the treatment of DR using Panax notoginseng primarily involved 28 biological processes and 10 related pathways. Further analyses indicated that angiogenesis, inflammatory reactions, and apoptosis may be the main processes involved in the treatment of DR with Panax notoginseng. In addition, we determined that the mechanism of intervention of Panax notoginseng in treating DR may involve five core targets, VEGFA, MMP-9, MMP-2, FGF2, and COX-2. Conclusion: Panax notoginseng may treat diabetic retinopathy through the mechanism of network pharmacological analysis. The underlying molecular mechanisms were closely related to the intervention of angiogenesis, inflammation, and apoptosis with VEGFA, MMP-9, MMP-2, FGF2, and COX-2 being possible targets.

show abstract

Diabetic Retinopathy: Battling the Global Epidemic

Cited by 50 publications

References 83 publications

miR‐30a‐5p inhibition promotes interaction of Fas⁺endothelial cells and FasL⁺microglia to decrease pathological neovascularization and promote physiological angiogenesis

miR‐30a‐5p inhibition promotes interaction of Fas⁺endothelial cells and FasL⁺microglia to decrease pathological neovascularization and promote physiological angiogenesis

The spatial relation of diabetic retinal neurodegeneration with diabetic retinopathy

Network Pharmacology-based Investigation of the Underlying Mechanism of Panax notoginseng Treatment of Diabetic Retinopathy

Contact Info

Product

Resources

About

Diabetic Retinopathy: Battling the Global Epidemic

Cited by 50 publications

References 83 publications

miR‐30a‐5p inhibition promotes interaction of Fas+endothelial cells and FasL+microglia to decrease pathological neovascularization and promote physiological angiogenesis

miR‐30a‐5p inhibition promotes interaction of Fas+endothelial cells and FasL+microglia to decrease pathological neovascularization and promote physiological angiogenesis

The spatial relation of diabetic retinal neurodegeneration with diabetic retinopathy

Network Pharmacology-based Investigation of the Underlying Mechanism of Panax notoginseng Treatment of Diabetic Retinopathy

Contact Info

Product

Resources

About

miR‐30a‐5p inhibition promotes interaction of Fas⁺endothelial cells and FasL⁺microglia to decrease pathological neovascularization and promote physiological angiogenesis

miR‐30a‐5p inhibition promotes interaction of Fas⁺endothelial cells and FasL⁺microglia to decrease pathological neovascularization and promote physiological angiogenesis